Monday, August 25, 2025

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Related stories

NVIDIA Unveils Spectrum-XGS to Link Data Centers for AI

NVIDIA has introduced NVIDIA® Spectrum-XGS Ethernet, a next-generation networking...

Meta Strikes Licensing Deal with Midjourney to Advance AI Image and Video Tools

Meta has announced a strategic licensing partnership with Midjourney...

Fivetran & S3NS Partner to Secure Data Movement in Europe

Fivetran, a global leader in automated data movement, has...

TransPerfect Acquires Unbabel for Language AI

TransPerfect, the world’s largest provider of language and AI...

Anthropic unveils higher ed advisory board, AI Fluency courses

Anthropic announced two major initiatives aimed at shaping the...
spot_imgspot_img

Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging. The study describes the validation of Cleerly’s artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification

In two trials, the CREDENCE and PACIFIC-1 studies comprised a total of 513 patients who underwent coronary CT angiography, myocardial perfusion imaging with single photon emission CT (SPECT), and fractional flow reserve derived from CT (FFRCT).

Also Read: Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors

For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up. Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia.

“This pivotal study was performed in two different international populations which shows that CCTA analyzed with the Cleerly AI-QCT ISCHEMIA device provides an accurate assessment of coronary ischemia,” said James P. Earls, MD, Chief Medical Officer of Cleerly. “These promising findings offer the possibility of a novel care paradigm for symptomatic coronary artery disease evaluation that performs comprehensive analysis of atherosclerosis, stenosis and ischemia from a single non-invasive CCTA test, which may offer the benefit of guiding clinical decision making for both coronary revascularization and medical therapy.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img